You're all sinking because you played with fire. Talented investors new that Acadia had something great because hitting these types of endpoints in a CNS trial is almost impossible. Also, the upside seen in CNS companies can rival almost any other field because CNS drugs (atypical antipsychotics or lyrica for example) go on to be used in multiple indications. Alzheimer's is next up and I believe this is one of the main reasons the FDA decided to give them this break. Acadia SHOULD NOT find a buyer. This is a $50/stock IMO. The reason is that the indications are endless and the existing data/safety is incredible.
So many areas will be explored. I know a bit about 2A blockade and method of action in the brain such as increased dopaminergic flow to the frontal lobes. Acadia is like Cephalon all over again but even better. I don't like shorts and you're all in trouble. However, I'm also not mean....I would seriously cover if I were you. You're going to get your clocks cleaned here. All my opinion, but I'm sick of all of you bashing so it's a little funny to see you get creamed. You've suffered enough...go away.